Amicogen Inc is a Korea-based company engaged in the development, production and distribution of enzymes, bio new materials and healthcare food. The Companyâ€™s products consist of special enzymes, N-acetylglucosamine (NAG), pinitol, D-Chiro-inositol (DCI), collagen peptides (CP) and protein A chromatography resins. The Company sells its products in domestic and overseas markets.

Employees

236

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
16/06/26	1,298.00 ₩	+0.31%	442,886
15/06/26	1,294.00 ₩	-0.77%	355,970
12/06/26	1,304.00 ₩	+0.69%	600,643
11/06/26	1,295.00 ₩	+2.13%	750,814
10/06/26	1,268.00 ₩	-3.13%	652,532

End-of-day quote Korea S.E.

More quotes

Income Statement and Estimates

More financial data

End-of-day quote Korea S.E. Other stock markets 16/06/2026			5-day change	1st Jan Change
1,298.00 ^KRW	+0.31%		-1.29%	-27.16%

05-14	Amicogen, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
03-23	Amicogen, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025	CI

Market Cap	91.45B 60.61M 52.23M 48.1M 45.16M 84.78M 5.73B 85.68M 568M 221M 2.81B 227M 223M 9.72B	P/E Ratio 2024	-4.02x	P/E Ratio 2025	-3.28x
Enterprise Value	178B 118M 102M 93.8M 88.07M 165M 11.18B 167M 1.11B 432M 5.47B 444M 434M 18.97B	EV / Sales 2024	1.86x	EV / Sales 2025	4.43x
Free-Float	95.13%	Yield 2024 *	-	Yield 2025	-

05-14	Amicogen, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
03-23	Amicogen, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
11-14	Amicogen, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
22/09/25	Amicogen, Inc.(KOSDAQ:A092040) added to S&P Global BMI Index	CI
20/08/25	Bio-Works Launches WorkBeads AffimAb Edge: Strategic Expansion in the Protein A Resin Market	CI
14/08/25	Amicogen, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025	CI
11/08/25	Amicogen, Inc. announced that it has received KRW 7 billion in funding from BIFIDO Co., Ltd.	CI
14/05/25	Amicogen, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025	CI
25/04/25	Amicogen, Inc.(KOSDAQ:A092040) dropped from S&P Global BMI Index	CI
19/03/25	Amicogen, Inc. Reports Earnings Results for the Full Year Ended December 31, 2024	CI
10/12/24	An undisclosed buyer agreed to acquire an unknown stake in Amicogen Biopharm Co., Ltd. from Amicogen, Inc. for KRW 54.7 billion.	CI
21/11/24	Enzynomics Co., Ltd. completed the acquisition of 37.32% stake in SKINMED Co., Ltd. from Amicogen, Inc..	CI
14/11/24	Amicogen, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024	CI

20/06/24	Bio-Works and Amicogen have concluded their technology transfer project.	AQ
10/09/21	Bio Works Technologies : Amicogen Inc enters into agreement to divest its ownership in Bio-Works	AQ
17/02/21	Bio Works Technologies : Works signs licensing agreement with Amicogen Inc to establish local manufacturing of agarose resins in South Korea	AQ

Amicogen, Inc. Stock

Stocks

A092040

KR7092040005

Biotechnology & Medical Research

Valuation: Amicogen, Inc.

Chart: Amicogen, Inc.

Latest news : Amicogen, Inc.

Press Releases: Amicogen, Inc.

News in other languages: Amicogen, Inc.

Quotes and Performance

Course Extremes

Managers and Directors: Amicogen, Inc.

Latest insider transactions

Bio Therapeutic Drugs

Financials

Company Profile

Quotes

Income Statement and Estimates

1 day	+0.31%
1 week	-1.29%
Current month	-17.59%
1 month	-21.95%
3 months	-5.19%
6 months	-51.48%
Current year	-27.16%

1 week	1,218	1,350
1 month	1,218	1,971
Current year	1,160	2,300
1 year	1,160	4,440
3 years	1,160	9,790
5 years	1,160	23,500
10 years	1,160	24,825

Manager	Title	Age	Since
Jjeo Pyo CEO	Chief Executive Officer	53	-
Young-Chul Yoon PRN	Corporate Officer/Principal	55	28/03/2024
Chun-Gu Kim AUD	Comptroller/Controller/Auditor	69	27/03/2025

Director	Title	Age	Since
Jun-Ho Kim BRD	Director/Board Member	56	26/02/2025
Jjeo Pyo BRD	Director/Board Member	53	-
Young-Chul Yoon BRD	Director/Board Member	55	28/03/2024

Date	Insider	Type	Main position	Quantity	% Market Cap.
03-03	Ji-Seong So	Buy	Director	435	0.0006%
03-03	Young-Chul Yoon	Buy	Director	109	0.0002%
02-27	Eun-seong Hwang	Buy		4,000	0.0072%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
AMICOGEN, INC.	+0.31%	-1.29%	-65.98%	-86.49%	60.27M
ARGENX SE	-0.71%	-0.29%	+56.45%	+107.18%	54.92B
WUXI APPTEC CO., LTD.	-1.22%	+2.25%	+43.78%	+38.45%	44.31B
BIONTECH SE	-0.01%	+5.18%	-14.44%	-19.16%	22.96B
INSMED INCORPORATED	-1.74%	-3.43%	-5.86%	+378.20%	21.12B
WUXI BIOLOGICS (CAYMAN) INC.	-2.91%	-1.18%	+7.21%	-36.53%	16.31B
GENMAB A/S	-2.38%	-3.38%	+5.53%	-41.88%	15.19B
EXELIXIS, INC.	-0.98%	-0.87%	+25.82%	+175.17%	13.32B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	+1.48%	+11.36%	+22.59%	-	12.48B
PHARMAESSENTIA CORPORATION	+4.10%	+7.02%	+104.41%	+226.33%	11.21B
Average	-0.38%	+2.64%	+17.95%	+82.36%	21.19B
Weighted average by Cap.	-0.74%	+2.01%	+31.05%	+94.14%

	2024	2025
Net sales	174B 115M 99.15M 91.31M 85.73M 161M 10.88B 163M 1.08B 420M 5.33B 432M 423M 18.46B	41.98B 27.82M 23.98M 22.08M 20.73M 38.92M 2.63B 39.33M 261M 102M 1.29B 104M 102M 4.46B
Net income	-52.79B -34.99M -30.15M -27.76M -26.07M -48.94M -3.31B -49.46M -328M -128M -1.62B -131M -129M -5.61B	-29.96B -19.86M -17.11M -15.76M -14.79M -27.78M -1.88B -28.07M -186M -72.54M -919M -74.52M -72.93M -3.19B
Net Debt	112B 73.91M 63.69M 58.65M 55.07M 103M 6.99B 104M 693M 270M 3.42B 277M 271M 11.86B	86.91B 57.6M 49.64M 45.71M 42.92M 80.57M 5.45B 81.42M 540M 210M 2.67B 216M 212M 9.24B